Moleculin Biotech, Inc. Posts Investor Presentation on Corporate Website

Moleculin Biotech, Inc., a pharmaceutical company based in Houston, Texas, has recently made an important disclosure. On December 18, 2024, the company revealed that it is utilizing a presentation for its corporate presentation, which has been uploaded to the company’s website. This presentation, marked as Exhibit 99.1 in a Form 8-K filing with the Securities and Exchange Commission, contains valuable information intended for public viewing.

As per Item 7.01 of the Form 8-K report, the information available in the presentation, as well as Exhibit 99.1 itself, is being furnished for public access. It is essential to note that this data will not be “filed” for the Securities Exchange Act of 1934 or incorporated by reference in any Exchange Act or Securities Act filings, except if explicitly identified for such purposes.

Additionally, the company disclosed under Item 9.01 of the filing that alongside the presentation, an Interactive Data File formatted as Inline XBRL (eXtensible Business Reporting Language) was included as Exhibit 104.

The signing of the document, as required by the Securities and Exchange Act of 1934, was executed on behalf of Moleculin Biotech, Inc. by Jonathan P. Foster, with the report being officially signed on December 18, 2024.

Investors and stakeholders interested in the contents of Moleculin Biotech’s latest corporate presentation are encouraged to access Exhibit 99.1 on the company’s website for further details.

This release signifies Moleculin Biotech’s commitment to transparent communication with its investors and the general public regarding the latest developments within the company.

This article is for informational purposes only and does not constitute financial advice or an endorsement of Moleculin Biotech, Inc.’s securities.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Moleculin Biotech’s 8K filing here.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.